Open access
Aug 2026
Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling
Cobicistat, a candidate MEST-inhibitory compound, exhibits favorable preclinical efficacy and safety, providing a promising candidate for targeted GC therapy, and functions as a key oncoprotein driving GC progression via NF-κB activation.
Hong-Tai Cao, Huili Ye, Wen-Tao Zhang et al.
· Frontiers in Oncology · 0 citations